Phase 2 N=20 Lymph Node Mapping in Finding Metastatic Disease in Patients With Sebaceous Gland Cancer of the Eyelid
Eyelid Sebaceous Gland Carcinoma
Primary: Sentinel Lymph Node Positivity — 2 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=150 Chalazion Conservative Treatment Trial
Chalazion Unspecified Eye, Unspecified Eyelid · Chalazion Left Eye, Unspecified Eyelid · Chalazion Right Eye, Unspecified Eyelid
Primary: Number of Participants With Complete Resolution — 13; 12; 11 participants
Phase 4 N=35 VISmodegib for ORbital and Periocular Basal Cell Carcinoma
Carcinoma, Basal Cell
Primary: The Number of Patients With a Score of 21 or Greater by the Visual Assessment Weighted Score (VAWS). — 34 Participants
Early Phase 1 N=15 Topical Bimatoprost for Chemical Blepharoplasty
Dermatochalasis
Primary: Graded Change in Dermatochalasis — .2679 units on a scale
N/A N=19 Intense Pulse Light Treatment With Meibomian Gland Expression of the Upper Eyelids in Dry Eye Disease
Dry Eye
Primary: Non-invasive Tear Break up Time (TBUT) — 3.9; 4.0 seconds
N/A N=16 Clinical Trial Comparing Two Non-Surgical Treatments for Severe Blepharoptosis
Blepharoptosis · Ptosis, Eyelid · Myasthenia Gravis
Primary: Interpalpebral Fissure (IPF) During Spontaneous Blink — 2.4; 4.1; 1.1 millimeters — p=<0.001
Phase 4 N=43 The Effect of Lumify™ Eyedrops on Eyelid Position
Eyelid Droop
Primary: Palpebral Fissure Height — 9.64; 9.66; 9.92; 9.96 milimeter
N/A N=264 Silicone Gel for Postsurgical Scars of the Eyelid
Scarring Due to Treatment
Primary: Post-operative Scarring - Erythema — 1.67; 1.70; 1.50; 1.65 score on a scale — p=0.48
Phase 4 N=401 Topical Antibiotic Prophylaxis for Eyelids
Antibiotic Side Effect · Eyelid; Wound · Eyelid Diseases
Primary: Number of Participants With Surgical Site Infections — 0; 5 Participants — p=0.025
Phase 4 N=18 Phenylephrine Versus Eyelid Taping for Muller's Muscle-Conjunctival Resection (MMCR) Evaluation
Ptosis, Eyelid
Primary: Mean MRD1 After Phenylephrine — 2.08 mm
N/A N=19 Clinical Trial to Improve the Magnetic Levator Prosthesis
Blepharoptosis · Ptosis, Eyelid · Myasthenia Gravis
Primary: Change in Interpalpebral Fissure During Eye Opening — 4.5; 6.9; 6.2; 6.3 millimeters — p=>=0.46
Phase 2 N=33 LEV102 Topical Gel in Acquired Blepharoptosis
Acquired Blepharoptosis
Primary: Percentage of Subjects With Treatment-Emergent Adverse Events [Safety and Tolerability]) — 0; 0; 0 Participants
N/A N=11 Magnetic Correction of Eye Lid Paralysis
Blepharoptosis · Lagophthalmos · Facial Paralysis
Primary: Rating Scale of Skin Integrity — 0.3 units on a scale
Phase 2 N=90 Phase 2 Study of XAF5 (XOPH5) Ointment for Reduction of Excess Eyelid Fat (Steatoblepharon)
Lower Eyelid Steatoblepharon (Excess Eyelid Fat)
Primary: Lower Eyelid Steatoblepharon Severity (LESS) Score--Clinician-Reported — 27; 6 participants — p=0.020
N/A N=7 Minimally Invasive Holmium:YAG Laser Blepharoplasty
Lower Eyelid Entropion
Primary: Change in Lower Eyelid Bags. — 5; 5 Participants
Phase 3 N=263 Safety and Efficacy Study of SUN-131 Transdermal System (TDS) as Compared to Placebo TDS in Patients With a Chalazion
Chalazion
Primary: The Proportions of Participants Who Experienced Complete Response of the Study Chalazion by Day 15 ± 1 — 28; 32 Participants — p=0.579
Phase 1 N=17 Demodex Blepharitis Treatment Study
Chronic Blepharitis
Primary: Change in the Number of Demodex Mites — -3; -0.4 Mites
N/A N=179 Epidemiologic Analysis of Change in Eyelash Characteristics With Age in Healthy Women
Health
Primary: Eyelash Length as Measured by Digital Image Analysis (DIA) — 7.33 Millimeters (mm)
Phase 2 N=46 Safety and Efficacy Study of RVL-1201 in Acquired Blepharoptosis
Blepharoptosis
Primary: Humphrey Visual Field — 9.8; 12.1; 11.1; 16.1 Points seen
Phase 2 N=24 Eyelid Androgen Treatment in Dry Eye
Aqueous Tear Deficiency · Meibomian Gland Dysfunction of Bilateral Eyes (Disorder)
Primary: Tear Break up Time — 0.0; 2.9 seconds
N/A N=1 Treatment With Intravitreal Avastin for Large Uveal Melanomas
Uveal Melanoma
Primary: The Response of Intravitreal Avastin in Causing a Clinically Significant Reduction in Uveal Melanoma Tumor Size (Base Height and Volume). — 1; 0; 0; 0 participants
N/A N=35 A Clinical Study of Systane® Lid Wipes in Brazil
Ocular Tolerance · Skin Tolerance
Primary: Number of Participants With a Contact-dermatitis Adverse Reaction — 0 participants
Phase 3 N=234 Study of Safety of RVL-1201 in Treatment of Blepharoptosis
Blepharoptosis
Primary: Mean Change From Baseline in Intraocular Pressure (IOP) at Day 84 — -0.6; -0.2; -0.6; -0.2 mmHg
N/A N=30 Impact of Soft Contact Lenses on Lid-Parallel Conjunctival Folds
Lid-Parallel Conjunctival Folds
Primary: Lid-Parallel Conjunctival Folds (LIPCOF) — 1.95; 1.75; 1.70; 1.40 Score
Phase 3 N=164 Study of Safety and Efficacy of RVL-1201 in the Treatment of Blepharoptosis
Blepharoptosis
Primary: Mean Change in Number of Points Seen on the Leicester Peripheral Field Test (LPFT) in RVL-1201 Group vs. Vehicle Group — 6.3; 2.1; 7.7; 2.4 Points seen — p=<0.0001
Phase 2 N=48 ET-01 in Subjects With Lateral Canthal Lines
Lateral Canthal Lines · Crow's Feet
Primary: Number of Participants With a Response Defined as IGA-C (Investigators Global Assessment) Score ≤ 2 and a SSA-C (Subject Self-Assessment) Score ≤ 2 — 2; 3; 4; 2…
N/A N=10 Twenty-four Hour Intraocular Pressure Patterns in Patients With Uncontrolled Thyroid Eye Disease
Thyroid Eye Disease
Primary: Change in IOP Before and After Orbital Decompression Surgery — 18 mVEq (Sensismed Triggerfish output unit)
Phase 3 N=140 Study of the Safety and Efficacy of RVL-1201 in the Treatment of Acquired Blepharoptosis
Acquired Blepharoptosis
Primary: Mean Change in Number of Points Seen on the Leicester Peripheral Field Test (LPFT) in RVL-1201 Group vs. Vehicle Group — 5.2; 1.5; 6.4; 2.2 Points seen — p=<0.0001
Phase 1 N=5 Effect of Ranibizumab on Malignant Conjunctival Neoplasia
Conjunctival Neoplasms
Primary: Number of Patients Assessed for Safety and Tolerability — 5 participants
Phase 3 N=50 Evaluation of Screening Methods for Treatment of Meibomian Gland Dysfunction
Chalazion · Dry Eye Syndromes
Primary: Association Between Screening Methods (Meibomian Gland Expression) and Treatment Effectiveness Outcomes (Total Meibomian Gland Score) — 0.4816 Correlation coefficient…